AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
CapsoVision, Inc.
Video analysis: CV
All videosNo video analysis for this stock yet. Request one from our team.
News: CV
Critical Contrast: Zimmer Biomet (NYSE:ZBH) versus CapsoVision (NASDAQ:CV)
Zimmer Biomet (NYSE: ZBH - Get Free Report) and CapsoVision (NASDAQ: CV - Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, profitability, analyst recommendations, institutional ownership, dividends, valuation and earnings. Profitability This table compares Zimmer Biomet and CapsoVision's net
BlackRock Inc. Acquires New Shares in CapsoVision, Inc. $CV
BlackRock Inc. purchased a new position in shares of CapsoVision, Inc. (NASDAQ: CV) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 1,896,088 shares of the company's stock, valued at approximately $14,372,000. BlackRock Inc. owned 3.80% of CapsoVision at
CapsoVision to Participate in Upcoming Investor Conferences
SARATOGA, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, plan to participate in the following upcoming investor conferences: H.C.
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings
[url="]Alnylam Pharmaceuticals, Inc[/url]. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology
CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript
CapsoVision, Inc. (CV) Q2 2026 Earnings Call Transcript
CapsoVision Q2 Earnings Call Highlights
CapsoVision NASDAQ: CV reported second-quarter revenue growth as sales of its CapsoCam Plus capsule endoscopy system increased, while the company advanced its artificial intelligence software rollout and development programs for colon and upper gastrointestinal applications.
CapsoVision Reports Second Quarter 2026 Financial Results
SARATOGA, Calif., Aug. 13, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today reported financial results and provided a business update for its second quarter ended June 30, 2026.
CapsoVision® Announces International Launch of AI Highlights
SARATOGA, Calif. , Aug. 03, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced the international launch of AI Highlights for the CapsoCam Plus system. AI Highlights is available within CapsoView and is being introduced in international markets, including the European Union.